In a 6 to 2 vote, the Oncologic Drug Advisory Committee determined that findings from the phase 3 AQUILA trial do/do not ...

Roger Li, MD, discusses factors influencing international doctors' attendance at the upcoming American Society of Clinical ...

In an interview with Targeted Oncology, C. Ola Langren, MD, discussed the continuing impact of the groundbreaking FDA ODAC ...

PT-112 monotherapy advances to phase 3 trial in metastatic castration-resistant prostate cancer after positive FDA end of ...

During a live event, Nathan M. Denlinger, DO, MS, discussed the PILOT and ALYCANTE trials of CAR T-cell therapy in transplant-ineligible B-cell lymphoma.

John L. Marshall, MD, discusses unmet needs in the targeted therapy space and the importance of optimizing dosing in colorectal cancer.

In an 8 to 1 vote, the Oncologic Drug Advisory Committee determined that findings from the phase 3 STARGLO trial are not applicable to patients in the US with diffuse large B-cell lymphoma.

In arm 1 of the trial, the dose-escalation portion, patients will receive mRNA-4106 at a test dose as monotherapy. In arm 2, ...

In the last year, there has been excitement about the use of MRD in multiple myeloma trials and new approaches to assessing ...

Prof Martin Dreyling discusses the shifting treatment landscape for patients with difficult-to-treat mantle cell lymphoma.

In separate live virtual events, Sarah A. Holstein, MD, PhD, and Shashank Cingam, MD, discuss options for a patient with relapsed/refractory multiple myeloma and the use of chimeric antigen receptor ...

During a Community Case Forum event, Antoinette R. Tan, MD, MHS, discussed the DESTINY-Breast04 and DESTINY-Breast06 trials ...